Drug Detail

Drug Name Binimetinib
Trade Name Mektovi
Synonyms ARRY-162|ARRY-438162|MEK162
Drug Descriptions

Mektovi (binimetinib) inhibits MEK1 and MEK2 resulting in inhibition of growth factor-mediated signaling and decreased tumor cell proliferation (PMID: 23587417). Mektovi (binimetinib) in combination with Braftovi (encorafenib) is FDA approved for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (FDA.gov).

DrugClasses MEK inhibitor (Pan) 20 MEK1 Inhibitor 20 MEK2 Inhibitor 18

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
MEK162 + FOLFOX
AZD6482 + Binimetinib
Binimetinib + Cetuximab + Encorafenib
MEK162 + Imatinib mesylate
MEK162 + Nilotinib
AZD8055 + Binimetinib
Binimetinib + Ribociclib
AZD6482 + Binimetinib + LGX818 + BYL719
Alpelisib + Binimetinib
Binimetinib + BKM120
Binimetinib + Encorafenib
LGX818 + MEK162 + BGJ398
AZD6482 + Binimetinib + LGX818
MEK162 + AEB071
MEK162 + Paclitaxel
Binimetinib + Pembrolizumab
Binimetinib + Palbociclib
Avelumab + Binimetinib + Talazoparib
Binimetinib + Docetaxel
LGX818 + MEK162 + INC280
Binimetinib + FOLFIRI
Binimetinib + Pictilisib
AZD6482 + Binimetinib + NVP-AEW541
Binimetinib + Ipilimumab + Nivolumab
Bevacizumab + Binimetinib + Pembrolizumab
MEK162 + Gemcitabine + Cisplatin
Binimetinib + Everolimus
BEZ235 + Binimetinib
MEK162 + Erlotinib
MEK162 + Carboplatin + Pemetrexed
Binimetinib + FOLFIRI + Pembrolizumab
MEK162 + Idarubicin + Cytarabine
Binimetinib + Encorafenib + Ribociclib
LGX818 + MEK162 + BKM120
AZD6482 + Binimetinib + LGX818 + NVP-AEW541
APS-2-79 + Binimetinib
Binimetinib Mektovi (binimetinib) inhibits MEK1 and MEK2 resulting in inhibition of growth factor-mediated signaling and decreased tumor cell proliferation (PMID: 23587417). Mektovi (binimetinib) in combination with Braftovi (encorafenib) is FDA approved for use in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (FDA.gov).
Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
AZD6482 + Binimetinib + BYL719
Binimetinib + Nivolumab
GSK2636771 + Binimetinib
Avelumab + Binimetinib
Binimetinib + Pexidartinib
Gemcitabine + MEK162 + Oxaliplatin